Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082036 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM5LMNASIGMAR1 | |
| SCHEMBL3083479 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM5LMNASIGMAR1 | |
| SCHEMBL3311708 | 0.89 | CHRM2 (0.54) | CHRM2CHRM4CHRM5LMNASIGMAR1 | |
| Hydrochloric Acid SCHEMBL3931307 | 0.88 | CHRM2 (0.57) | CHRM2CHRM4CHRM5LMNASIGMAR1 | |
| SCHEMBL1988535 | 0.84 | CHRM2 (0.53) | CHRM2CHRM4CHRM5SIGMAR1GBA1 | |
| SCHEMBL3718240 | 0.84 | CHRM2 (0.55) | CHRM2CHRM4CHRM5ALDH1A1KMT2A | |
| SCHEMBL9749461 | 0.83 | CHRM2 (0.56) | CHRM2CHRM4CHRM5LMNASIGMAR1 | |
| SCHEMBL1988057 | 0.82 | CHRM2 (0.50) | CHRM2CHRM4CHRM5LMNASIGMAR1 | |
| SCHEMBL637410 | 0.81 | CHRM2 (0.51) | CHRM2CHRM4CHRM5LMNASIGMAR1 | |
| SCHEMBL636999 | 0.81 | CHRM2 (0.58) | CHRM2CHRM4CHRM5LMNASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| EP-3638676-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018228909-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-20 | — | — | WO | disclosed |
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| WO-2008143856-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BET1, HRH1, GRIN1 | CHRM2 576/4885CHRM4 295/4885CHRM5 614/4885 |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | GRIN1, BET1, HRH1 | CHRM2 506/4885CHRM4 255/4885CHRM5 572/4885 |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CHRM2 700/4885CHRM4 364/4885CHRM5 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.